31 stories mentioning HKG:1177Updated 3d ago
Every FINWIRES story that references HKG:1177, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Sino Biopharmaceutical (HKG:1177) will take an additional 5% stake in its CT Tianqing subsidiary in a deal worth 4.48 billion yuan.The acquisition will increase Sino Biopharm's indirect stake in CT Tianqing to 65% from 60%, according to a Friday filing on the Hong Kong bourse. Completion is expected Sept. 16, subject to the satisfaction or waiver of the transaction conditions.
Sino Biopharmaceutical (HKG:1177) said data from two phase I studies of TQC3721 dry powder inhaler was presented at the 2026 annual meeting of the European Respiratory Society.The clinical trial tested the safety and efficacy of the inhaler, developed by unit Chia Tai Tianqing Pharmaceutical Group, in patients with chronic obstructive pulmonary disease, according to a Monday filing with the Hong Kong bourse.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group obtained investigational new drug approval for TQB6426 from the U.S. Food and Drug Administration.The drug is intended for advanced malignant tumors, according to a Thursday Hong Kong bourse filing.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group entered into an exclusive license and supply agreement with Cipla for cancer drug TQB2102.The group will grant Cipla an exclusive licence to develop and commercialize TQB2102 in India, South Africa, and five other emerging markets, according to a Monday Hong Kong bourse filing.Cipla will be responsible for local clinical development, regulatory activities, and commercialization, while Chia Tai Tianqing Pharmaceutical will continue to manufacture and supply the drug.The group will receive an upfront payment, and is eligible for potential development, regulatory, and sales milestone payments of up to $123 million, as well as tiered double-digit royalties.
Sino Biopharmaceutical (HKG:1177) has an average rating of buy and mean price target of HK$8.48, according to analysts polled by FactSet.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical obtained clinical trial approval for the TQF6422 injection from China's National Medical Products Administration.The drug will be tested for weight management in adult patients with obesity, or in overweight adults with at least one weight-related comorbidity.
Sino Biopharmaceutical (HKG:1177) reported 3.43 billion yuan in profit attributable to owners for the first half, compared with 3.39 billion yuan a year ago, a Wednesday bourse filing showed.EPS moved to 0.1903 yuan from 0.188 yuan year over year.For the six months ended June 30, revenue was 19.4 billion yuan, versus 17.6 billion yuan previously, the pharma company said.The company declared an interim dividend of HK$0.07 per share, payable Sept. 24 to shareholders of record as of Sept. 4. It paid HK$0.05 per share in the year-ago period.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's Benmelstobart Injection obtained marketing approval from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approval is for use of the drug in combination with chemotherapy and sequentially followed by Anlotinib Hydrochloride Capsules for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's Second-Generation Flurbiprofen Patch obtained marketing approval from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approval is for the indications of analgesia and anti-inflammatory treatment for osteoarthritis, shoulder periarthritis, tendinitis and tenosynovitis, peritendinitis, lateral epicondylitis, muscle pain, and swelling and pain due to trauma.The product was also granted a four-year data protection period by the regulator.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's new drug application for TQB3909 Tablet was accepted by China's National Medical Products Administration.The product has been developed for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, according to a Tuesday Hong Kong bourse filing.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's TQB2102 was granted breakthrough therapy designation by China's National Medical Products Administration.The drug is for adult patients with unresectable or metastatic HER2-low breast cancer.This is the third breakthrough therapy designation granted to the drug.
Sino Biopharmaceutical (HKG:1177) formed an Indonesian joint venture with Tempo Scan Pacific to commercialize pharmaceutical products in Indonesia.The venture, Tempo CTTQ Biopharmaceutical Indonesia, is 51%-owned by Sino Biopharma and 49%-owned by Tempo Scan, according to a Monday Hong Kong bourse filing.The JV will focus on regulatory affairs, clinical trials, market entry and commercialization of pharmaceutical products, while evaluating opportunities for manufacturing in Indonesia in the future.Several products have already obtained regulatory approval or are under regulatory review.
Sino Biopharmaceutical (HKG:1177) has an average rating of buy and mean price target of HK$7.97, according to analysts polled by FactSet.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical obtained clinical trial approval for the IM-101 injection from China's National Medical Products Administration.The drug candidate has been developed for the treatment of chronic hepatitis B, according to a Thursday Hong Kong bourse filing.
Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's TRD205 obtained breakthrough therapy designation from China's National Medical Products Administration.The move came following positive results from a phase II clinical trial of the drug for chronic post-surgical neuropathic pain, according to a Tuesday Hong Kong bourse filing.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group got acceptance for the TQB3454 tablet from China's National Medical Products Administration.The acceptance is for use of the drug to treat advanced biliary tract cancer harboring IDH1 mutations, according to a Friday Hong Kong bourse filing.
Sino Biopharmaceutical (HKG:1177) said subsidiary Chia Tai Tianqing Pharmaceutical expanded its collaboration with GlaxoSmithKline to commercialize two respiratory products in mainland China.Chia Tai Tianqing will obtain commercialization rights for GSK's Trelegy Ellipta and Anoro Ellipta in mainland China and will handle importation, distribution, hospital access and promotional activities for the products, according to a Hong Kong bourse filing on Wednesday.The products are combination inhalation therapies used in the treatment of respiratory conditions.
Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's new drug application for ropivacaine hydrochloride sustained-release solution was accepted by China's National Medical Products Administration.The acceptance is for the drug as a postoperative long-acting analgesic in adults, according to a Friday Hong Kong bourse filing.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group obtained marketing approval for the Peceleganan Spray, according to a Tuesday Hong Kong bourse filing.The drug was developed under an exclusive partnership by Chia Tai Tianqing Pharmaceutical.The approval is for the treatment of wound infections secondary to first-degree or superficial second-degree burns and scalds caused by Staphylococcus epidermidis, Staphylococcus haemolyticus and Acinetobacter baumannii.
Sino Biopharmaceutical (HKG:1177) unit LaNova Medicines' new drug application for tecotabart vedotin was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The product is intended for the treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Showing 1-20 of 31
